Company intelligence / Profile preview

Ubiquitome

Auckland, New Zealand

Ownership: Private
Employees: ~10
Development stage: Other

Overview

Ubiquitome markets the Liberty16 and Liberty16 Pro handheld, battery-powered, cloud-connected real-time PCR instruments, including use under FDA Emergency Use Authorization with the SalivaDirect protocol for detection of SARS-CoV-2 RNA, and supports broader clinical, environmental, and agricultural molecular testing.[2][6]

Therapeutic areas: Infectious Diseases
Modalities: DeviceNon-pharmacological therapy
Industry: Molecular Diagnostics

Partnerships

Yale School of Public Health (SalivaDirect protocol use on Liberty16)[2]NIH RADx program funding and collaboration for COVID-19 testing technology development[4]

Beyond the preview

Go deeper on Ubiquitome.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ubiquitome.

Explore the full profile